Equities Analysts Issue Forecasts for Apellis Pharmaceuticals Inc’s FY2020 Earnings (NASDAQ:APLS)

Share on StockTwits

Apellis Pharmaceuticals Inc (NASDAQ:APLS) – Analysts at Cantor Fitzgerald issued their FY2020 earnings estimates for Apellis Pharmaceuticals in a research report issued on Thursday, August 1st. Cantor Fitzgerald analyst E. Piros expects that the company will post earnings per share of ($4.23) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $50.00 target price on the stock.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.20).

Several other research firms have also recently weighed in on APLS. ValuEngine cut Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Cowen set a $40.00 price objective on Apellis Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 31st. Oppenheimer started coverage on Apellis Pharmaceuticals in a research note on Tuesday, July 9th. They issued an “outperform” rating and a $52.00 target price for the company. JPMorgan Chase & Co. upgraded Apellis Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $35.00 to $49.00 in a research note on Friday, July 12th. Finally, Zacks Investment Research cut Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $45.14.

NASDAQ APLS opened at $26.08 on Monday. Apellis Pharmaceuticals has a fifty-two week low of $11.45 and a fifty-two week high of $29.89. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.67 and a quick ratio of 8.67. The stock has a 50 day simple moving average of $26.38.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Apellis Pharmaceuticals by 59.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock valued at $75,000 after buying an additional 1,099 shares in the last quarter. SG Americas Securities LLC bought a new position in Apellis Pharmaceuticals during the 1st quarter valued at approximately $112,000. BNP Paribas Arbitrage SA increased its position in Apellis Pharmaceuticals by 250,533.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,519 shares of the company’s stock valued at $147,000 after buying an additional 7,516 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Apellis Pharmaceuticals by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock valued at $161,000 after buying an additional 9,541 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Apellis Pharmaceuticals by 146.0% during the 4th quarter. Bank of America Corp DE now owns 17,533 shares of the company’s stock valued at $231,000 after buying an additional 10,407 shares in the last quarter. Institutional investors own 63.48% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Recommended Story: Intrinsic Value

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Markel Corp Acquires 2,400 Shares of JPMorgan Chase & Co.
Markel Corp Acquires 2,400 Shares of JPMorgan Chase & Co.
Walt Disney Co  is K.J. Harrison & Partners Inc’s 10th Largest Position
Walt Disney Co is K.J. Harrison & Partners Inc’s 10th Largest Position
Walt Disney Co  Holdings Boosted by Matthew Goff Investment Advisor LLC
Walt Disney Co Holdings Boosted by Matthew Goff Investment Advisor LLC
McKinley Carter Wealth Services Inc. Has $1.34 Million Position in Cisco Systems, Inc.
McKinley Carter Wealth Services Inc. Has $1.34 Million Position in Cisco Systems, Inc.
Qube Research & Technologies Ltd Lowers Stock Holdings in Cisco Systems, Inc.
Qube Research & Technologies Ltd Lowers Stock Holdings in Cisco Systems, Inc.
Cisco Systems, Inc.  Shares Sold by Quest Capital Management Inc. ADV
Cisco Systems, Inc. Shares Sold by Quest Capital Management Inc. ADV


© 2006-2019 Ticker Report